It's a bit incongruous, but industrial manufacturing specialist Roper� (NYSE: ROP ) is now the proud owner of Managed Health Care Associates, a New Jersey-based supplier of services for�alternate site health-care providers.�The transaction was valued at approximately $1 billion, and was funded from Roper's�available cash and borrowings under its credit facility.
MHCA�negotiates discounted contracts with pharmaceutical manufacturers and medical equipment suppliers on behalf of nursing home operators, or assisted living facilities that operate outside of a traditional hospital setting.
When the deal was announced last month,�Roper's Chairman, President and CEO�Brian Jellison said:
MHA's powerful technology tools and proven customer-service model continue to drive growth in their multiple niches. The company has attractive cash return characteristics and generates substantial recurring revenue through long-term customer relationships and very high retention rates.
Best Recreation Companies To Watch In Right Now: Oramed Pharmaceuticals Inc (ORMP)
Oramed Pharmaceuticals Inc., incorporated on March 10, 2011, is a development-stage pharmaceutical company. The Company is engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, use of orally ingestible capsules, tablets or pills for delivery of other polypeptides. The Company owns oral dosage form drug portfolio, it is, on an on-going basis, considering in-licensing and other means of obtaining additional technologies to complement and/or expand the product portfolio. The Company�� products include ORMD-0801 - Oral Insulin Capsule and ORMD-0901 - Oral Exenatide.
The Company focuses to conduct research and development on the technology covered by the patent application Methods and Composition for Oral Administration of Proteins. Through its research and development efforts, it focuses to develop an oral dosage form that will withstand the chemical environment of the stomach and intestines and will be effective in delivering active insulin for the treatment of diabetes. It intends to conduct the clinical trials to file an Investigational New Drug (IND), application with the United States Food and Drug Administration (FDA). It also focuses to conduct research and development by deploying its drug delivery technology for the delivery of other polypeptides in addition to insulin, and to develop other pharmaceutical products.
Advisors' Opinion:- [By Ben Levisohn]
Oramed Pharmaceuticals (ORMP) has dropped 19% to $12.11 after the company said it would sell nearly 1.6 million shares of stock for $10 a share.
BP plc (BP) has fallen 0.7% to $47.24 after a U.S. judge refused its request to revise the way damages from the Deepwater Horizon oil spill are calculated.
- [By Lisa Levin]
Oramed Pharmaceuticals (NASDAQ: ORMP) shares moved up 21.26% to $14.20. The volume of Oramed Pharmaceuticals shares traded was 621% higher than normal. Oramed shares have jumped 187.01% over the past 52 weeks, while the S&P 500 index has gained 28.75% in the same period.
- [By Lisa Levin]
Oramed Pharmaceuticals (NASDAQ: ORMP) shares moved up 15.68% to $17.85. The volume of Oramed Pharmaceuticals shares traded was 971% higher than normal. Oramed received patent allowance in Israel, Australia for platform technology in oral delivery of proteins.
Top 5 Tech Companies To Watch In Right Now: DigitalGlobe Inc (DGI)
DigitalGlobe, Inc. provides commercial earth imagery products and information services worldwide. It collects imagery products and services through its QuickBird, WorldView-1, and WorldView-2 satellites, as well as aerial and satellite imagery from third party suppliers. The company offers a range of online and offline distribution options, including desktop software applications; Web services, which provide direct online access to the company�s image library; file transfer protocol; physical media, such as CD, DVD, and hard drive; and direct access program that facilitates certain customers to task and download data from its WorldView-1 and WorldView-2 satellites. Its imagery products and services support various uses, including defense, intelligence and homeland security, mapping and analysis, environmental monitoring, oil and gas exploration, and infrastructure management. DigitalGlobe, Inc. serves defense contractors; civil government agencies; providers of location-b ased services; and various companies in energy, telecommunications, utility, forestry, mining, financial services, environmental, and agricultural industries through direct and indirect channels. The company was formerly known as EarthWatch, Incorporated and changed its name to DigitalGlobe, Inc. in August 2002. DigitalGlobe, Inc. was founded in 1993 and is headquartered in Longmont, Colorado. DigitalGlobe, Inc. operates as a subsidiary of Morgan Stanley & Co. LLC.
Advisors' Opinion:- [By Seth Jayson]
DigitalGlobe (NYSE: DGI ) reported earnings on May 7. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), DigitalGlobe missed estimates on revenues and beat expectations on earnings per share.
Top 5 Tech Companies To Watch In Right Now: Durata Therapeutics Inc (DRTX)
Durata Therapeutics, Inc., incorporated on November 4, 2009, is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia.
As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin. Dalbavancin achieved its primary efficacy endpoint of non-inferiority in each of these three completed Phase III clinical trials when compared to linezolid, cefazolin or vancomycin, three of the standard-of-care agents for uncomplicated skin and skin structure infections (uSSSI), and complicated skin and skin structure infections (cSSSI). Its two ongoing Phase III clinical trials are designed to compare dalbavancin to vancomycin, with an option to switch to oral linezolid, under the new FDA draft guidance.
The Company competes with Pfizer, Cubist Pharmaceuticals, Inc., Theravance, Inc., Forest Laboratories, Inc., Sanofi-Aventis Ltd., The Medicines Company, Trius Therapeutics, Inc., Cempra, Inc., Rib-X Pharmaceuticals, Inc., Paratek Pharmaceuticals, Inc., Nabriva Therapeutics AG, Tetraphase Pharmaceuticals, Inc. and Furiex Pharmaceuticals, Inc.
Advisors' Opinion:- [By Lisa Levin]
Durata Therapeutics (NASDAQ: DRTX) shares climbed 5.30% to $14.18. The volume of Durata Therapeutics shares traded was 861% higher than normal. The FDA Advisory Committee unanimously recommended the approval of Durata's Dalvance.
- [By Bob's Stocks]
Durata Therapeutics (DRTX) is developing Dalbavancin, a once a week, intravenous antibiotic product candidate, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. The company is expected to file a NDA (New Drug Application) at any moment and MAA (Marketing Authorization Application) at the end of 2013.
Top 5 Tech Companies To Watch In Right Now: Mobileye NV (MBLY)
Mobileye N.V., incorporated in 2001, designs and develops software and related technologies for camera-based advanced driver assistance systems (ADAS). The Company�� software algorithms and EyeQ system on a chip (SOC) perform detailed interpretations of the visual field in order to anticipate possible collisions with other vehicles, pedestrians, cyclists, animals, debris and other obstacles. Its products are also able to detect roadway markings such as lanes, road boundaries, barriers and similar items, as well as to identify and read traffic signs and traffic lights. The Company operates in two segments: the original equipment manufacturer (OEM) segment and the AM segment. The OEM segment supplies the software algorithms and EyeQ chip that are the core technology of the complete ADAS to the Tier 1 companies that are the system integrators for the automotive industry. In the AM segment, the Company sells a complete system, which includes its software algorithms and EyeQ chip, as well as the camera and other necessary components.
The complete system offers a variety of ADAS functions to end, including commercial fleet owners, fleet management system providers, new vehicle dealers and importers. Its software activity is divided into algorithms, which are the engines for extracting meaningful information from video; and application software. Its visual interpretation algorithms consist of road signs interpretation, object detection, range and time-to-contact (TTC) to targets, motion-based measurements, pattern recognition and lighting functions. Road signs interpretation consists of lane markings, curbs, road edge, barriers, and other information that allows high-level control systems to make sense of where the host car is located relative to the roadway. Object detection includes pattern recognition of vehicles, pedestrians and (large) animals for collision avoidance.
Motion-based measurements include the flow of pixels along a sequence of images due to camera motion provides! three-dimensional (3D) cues that are analyzed in many levels of the system. This analysis includes validation filters for object detection engines (vehicles, pedestrians, animals); separating moving objects from the background; detecting general (not model-based) objects; detecting debris (of at least 10 centimeters in height) from 50 meters away; reconstructing the road profile in order to detect bumps and potholes; generating a 3D map of the visual field using the principle of structure from motion, which is the process of estimating 3D structures from two dimensional (2D) image sequences, and which may be coupled with local motion signals, and fusing 3D and image pattern recognition to aid in scene interpretation, all of which will also support automated-driving functionality.
It has developed multiclass classifiers to enable traffic sign detection, traffic light detection and detection of other structures from the scene that are useful for supporting hands-free driving. Its adaptive high beam control (AHC) is enabled by a set of algorithms that read and interpret the spots of light in the night scene to determine when to turn on or off the high beam. Its aftermarket customers include commercial and governmental fleets, telematics providers and insurance companies. Its Tier 1 customers include Magna Electronics Inc., TRW Automotive Holdings Corp., Autoliv, Inc., Delphi Automotive Plc, Gentex Corporation, Kansei Corporation, Leopold Kostal GmbH and Mando Corporation as well as Bendix Corporation and Mobis Transportation Alternatives, Inc. working jointly with TRW.
Advisors' Opinion:- [By WWW.DAILYFINANCE.COM]
Mark Lennihan/APJack Ma is the founder of Alibaba. There has been no shortage of debutantes on Wall Street lately. Dozens of companies went public last quarter -- many of them names you know, or that you will know soon. These some of the more intriguing initial public offerings to come out of this past quarter. El Pollo Loco (LOCO) Fast casual has been the place to be for investing in the restaurant industry, and that helped pave the way for this California-based chain specializing in citrus-marinated chicken to go public in July at $15 a share. Investors won't be impressed by its slow yet calculated expansion. It had grown from 398 locations to just 401 in the year leading up to its IPO. However, El Pollo Loco's store-level performance has been impressive. It posted a 5.4 percent increase in comparable-restaurant sales in its first quarter as a public company. That is certainly better than the average fast-food or casual-dining chain out there, once again validating the fast-casual model, where chains offer the convenience of fast food but the quality of traditional casual-dining restaurants. Mobileye (MBLY) The push to develop self-driving cars is really getting traction, a fact that became even more apparent last week when Tesla (TSLA) showed off an updated sedan that uses a dozen sensors to do everything from adjusting speed in accordance with speed limit signs when it's on cruise control to switching lanes automatically when the sensors see an opening in traffic after the driver triggers the turn signal. But clever sensors notwithstanding, self-driving cars won't happen without serious software, and that's where Mobileye comes in. The Israeli company provides software and chips for camera-based advanced driver assistance systems. This will likely become a competitive market in the future, but for now Mobileye is seen as a leading pioneer in self-driving vehicles. Its share price has roughly doubled since it went public at $25 just two months ago. Re
- [By Jake Mann]
One such name that does intrigue me is that of Mobileye NV (NYSE: MBLY).
...Ever see the cars in the movie I Robot? Well this is Sci Fi starting to come to life in a way. Think about it, who would have thought GPS would be standard in cars back 10-15 years ago. Now we are starting to cross the threshold of letting the car do the driving for you more and more?
- [By Tiernan Ray]
And lastly, Model S will add what’s known as “semi-autonomous driver-assistance system,” or SADAS, which, he contends, will use cameras from sensor maker MobileEye (MBLY).
- [By Ben Levisohn]
Tesla has confirmed that it has begun shipping Model S vehicles equipped with camera safety systems to comply with European safety ratings, and press reports indicate that Mobileye (MBLY) may be the [advanced driver assistance systems, or] ADAS supplier. Moreover, Elon has already stated he plans to bring semi-autonomous driving capability to market by 2016.
No comments:
Post a Comment